The benefit of maintaining bipolar I patients on monotherapy with oral ZYPREXA at a dose of 5 to 20 mg/day, afterachieving a responder status for an average duration of 2 weeks, was demonstrated in a controlled trial [seeClinical Studies] . The healthcareprovider who elects to use ZYPREXA ...
weakness, hypertension, and convulsion. The potential for onset of an event is greatest within the first hour. The majority of cases have occurred within the first 3 hours after injection; however, the event has occurred after 3 hours. Following the 3-hour observation period, healthcare professi...
The benefit of maintaining bipolar I patients on monotherapy with oral ZYPREXA at a dose of 5 to 20 mg/day, afterachieving a responder status for an average duration of 2 weeks, was demonstrated in a controlled trial [seeClinical Studies] . The healthcareprovider who elects to use ZYPREXA ...
The benefit of maintaining bipolar I patients on monotherapy with oral ZYPREXA at a dose of 5 to 20 mg/day, afterachieving a responder status for an average duration of 2 weeks, was demonstrated in a controlled trial [seeClinical Studies] . The healthcareprovider who elects to use ZYPREXA ...
ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with schizophrenia and bipolar I mania. Efficacy was demonstrated in 3 short-term (24 hours of IM treatment) placebo-controlled trials in agitated adult inpatients with: schizophrenia or bipolar Idisorder (manic or mixed...
ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with schizophrenia and bipolar I mania. Efficacy was demonstrated in 3 short-term (24 hours of IM treatment) placebo-controlled trials in agitated adult inpatients with: schizophrenia or bipolar Idisorder (manic or mixed...